

Multiple receptors contribute to the behavioral effects of

Neuropharmacology

61, 364-381

DOI: [10.1016/j.neuropharm.2011.01.017](https://doi.org/10.1016/j.neuropharm.2011.01.017)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Research on the Human Experience of Spirituality Following the Ingestion of "Magic"™ Psilocybin Mushrooms: An Annotated Bibliography for Social Workers and Other Health Care Professionals. SSRN Electronic Journal, 0, , .	0.4	1
2	Serotonin and Schizophrenia. Handbook of Behavioral Neuroscience, 2010, 21, 585-620.	0.7	15
3	Hallucinogens and Cannabinoids for Headache. Headache, 2012, 52, 94-97.	1.8	8
4	Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology, 2012, 62, 1381-1390.	2.0	32
5	Four factors underlying mouse behavior in an open field. Behavioural Brain Research, 2012, 233, 55-61.	1.2	77
8	Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 244-252.	2.5	39
9	LSD helps to treat alcoholism. Nature, 2012, , .	13.7	2
11	Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Testing and Analysis, 2012, 4, 556-576.	1.6	154
12	Behavioral effects of 1±,1±,1²,1²-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology, 2012, 221, 709-718.	1.5	33
13	Characterization of the head-twitch response induced by hallucinogens in mice. Psychopharmacology, 2013, 227, 727-739.	1.5	139
14	A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. American Journal of Drug and Alcohol Abuse, 2013, 39, 291-297.	1.1	15
15	Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice. Neuropharmacology, 2013, 70, 218-227.	2.0	42
16	Toxicological Findings of Synthetic Cannabinoids in Recreational Users. Journal of Analytical Toxicology, 2013, 37, 534-541.	1.7	116
17	Broadband Cortical Desynchronization Underlies the Human Psychedelic State. Journal of Neuroscience, 2013, 33, 15171-15183.	1.7	364
18	Gray colored glasses: Is major depression partially a sensory perceptual disorder?. Journal of Affective Disorders, 2013, 151, 418-422.	2.0	37
19	Neuropharmacology of Lysergic Acid Diethylamide (LSD) and Other Hallucinogens. , 2013, , 625-635.		3
20	Serotonergic hallucinogens differentially modify gamma and high frequency oscillations in the rat nucleus accumbens. Psychopharmacology, 2013, 228, 271-282.	1.5	31
21	Cannabinoids and Hallucinogens for Headache. Headache, 2013, 53, 447-458.	1.8	44

#	ARTICLE	IF	CITATIONS
22	Bioactive Alkaloids from Fungi: Psilocybin. , 2013, , 523-552.		6
23	Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence. CNS Drugs, 2013, 27, 301-319.	2.7	111
24	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-<i>N,N</i>-Dimethyltryptamine, and the Impact of CYP2D6 Status. Drug Metabolism and Disposition, 2013, 41, 975-986.	1.7	24
25	Serotonergic hallucinogens as translational models relevant to schizophrenia. International Journal of Neuropsychopharmacology, 2013, 16, 2165-2180.	1.0	51
26	â€œNoidsâ€•in a nutshell: everything you (donâ€™t) want to know about synthetic cannabimimetics. Advances in Dual Diagnosis, 2014, 7, 137-148.	0.3	21
27	Hallucinogens. , 2014, , 533-552.		3
28	Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology, 2014, 77, 200-207.	2.0	95
29	Alternative Drugs of Abuse. Clinical Reviews in Allergy and Immunology, 2014, 46, 3-18.	2.9	15
30	Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology, 2014, 83, 1-8.	2.0	49
31	Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro. Psychopharmacology, 2014, 231, 2771-2783.	1.5	26
32	Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds. Neuropharmacology, 2014, 83, 18-27.	2.0	15
33	Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. Journal of Psychopharmacology, 2014, 28, 49-54.	2.0	72
34	Psilocybin â€“ Summary of knowledge and new perspectives. European Neuropsychopharmacology, 2014, 24, 342-356.	0.3	167
35	Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology, 2014, 231, 875-888.	1.5	54
36	Licit and Illicit Drug Use in Cluster Headache. Current Pain and Headache Reports, 2014, 18, 413.	1.3	28
37	Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990â€“2014. Pharmacological Reports, 2014, 66, 343-352.	1.5	20
38	The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 57-63.	2.5	50
39	Carcinogenicity of Chemicals: Assessment and Human Extrapolation. , 2014, , 1277-1330.		3

#	ARTICLE	IF	CITATIONS
40	N,N-Dimethyltryptamine-Induced Psychosis. <i>Clinical Neuropharmacology</i> , 2015, 38, 141-143.	0.2	18
41	Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice. <i>Toxins</i> , 2015, 7, 1018-1029.	1.5	35
42	Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?. <i>Journal of Psychopharmacology</i> , 2015, 29, 241-253.	2.0	171
43	Behavioural and neurotoxic effects of ayahuasca infusion (<i>Banisteriopsis caapi</i> and <i>Psychotria viridis</i>) in female Wistar rat. <i>Behavioural Processes</i> , 2015, 118, 102-110.	0.5	81
44	Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain. <i>Neuropharmacology</i> , 2015, 99, 210-220.	2.0	29
45	Bioactive Alkaloids of Hallucinogenic Mushrooms. <i>Studies in Natural Products Chemistry</i> , 2015, , 133-168.	0.8	15
46	The hallucinogenic world of tryptamines: an updated review. <i>Archives of Toxicology</i> , 2015, 89, 1151-1173.	1.9	196
47	Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). <i>Neuropharmacology</i> , 2015, 99, 546-553.	2.0	163
48	Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MS n , and LC-HR-MS-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 7831-7842.	1.9	41
49	Potential of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors. <i>Neuropharmacology</i> , 2015, 89, 342-351.	2.0	22
50	LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. <i>Journal of Psychopharmacology</i> , 2015, 29, 57-68.	2.0	317
51	Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. <i>Behavioural Brain Research</i> , 2015, 277, 99-120.	1.2	221
52	LSD enhances suggestibility in healthy volunteers. <i>Psychopharmacology</i> , 2015, 232, 785-794.	1.5	207
53	Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. <i>Behavioural Pharmacology</i> , 2016, 27, 309-320.	0.8	38
54	Effect of Hallucinogens on Unconditioned Behavior. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 36, 159-199.	0.8	63
55	Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. <i>Lancet Psychiatry</i> , 2016, 3, 481-488.	3.7	168
56	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. <i>Lancet Psychiatry</i> , 2016, 3, 619-627.	3.7	988
57	Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5119-5124.	3.3	125

#	ARTICLE	IF	CITATIONS
58	Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. <i>Acta Pharmaceutica Sinica B</i> , 2016, 6, 492-503.	5.7	4
59	Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats. <i>Neurotoxicity Research</i> , 2016, 30, 606-619.	1.3	22
60	A Profile of Those Who Use Hallucinogenic Mushrooms. , 2016, , 794-800.		3
61	Psilocybin and Peak Experiences. , 2016, , 866-874.		0
62	Semantic activation in LSD: evidence from picture naming. <i>Language, Cognition and Neuroscience</i> , 2016, 31, 1320-1327.	0.7	24
63	Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain. <i>EBioMedicine</i> , 2016, 11, 262-277.	2.7	53
64	Psychedelics in the treatment of unipolar mood disorders: a systematic review. <i>Journal of Psychopharmacology</i> , 2016, 30, 1220-1229.	2.0	131
65	Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2016, 54, 21-24.	0.3	15
66	Return of the lysergamides. Part I: Analytical and behavioural characterization of 1- <i>propionyl</i> -lysergic acid diethylamide (1P- <i>LS</i>). <i>Drug Testing and Analysis</i> , 2016, 8, 891-902.	1.6	64
67	NPS: Medical Consequences Associated with Their Intake. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 351-380.	0.8	29
68	The Toxicology of New Psychoactive Substances. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 190-216.	1.0	39
69	Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms. <i>Pharmacological Reports</i> , 2016, 68, 608-615.	1.5	9
70	Lysergic acid diethylamide: a drug of use™?. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 214-228.	1.2	35
71	Psychedelics. <i>Pharmacological Reviews</i> , 2016, 68, 264-355.	7.1	990
72	The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT 1A and 5-HT 2A receptors. <i>Neuropharmacology</i> , 2016, 101, 370-378.	2.0	21
73	Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert) mice. <i>Behavioural Brain Research</i> , 2016, 296, 47-52.	1.2	23
74	Analytical characterization of <i>N,N</i> -diethyltryptamine (DALT) and 16 ring-substituted derivatives. <i>Drug Testing and Analysis</i> , 2017, 9, 115-126.	1.6	8
75	Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 593-609.	1.4	65

#	ARTICLE	IF	CITATIONS
76	Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. <i>Drug Metabolism Reviews</i> , 2017, 49, 84-91.	1.5	123
77	Pharmacology and Toxicology of N-Benzylphenethylamine (â€œNBOMeâ€) Hallucinogens. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 32, 283-311.	0.8	76
78	Neuropharmacology of New Psychoactive Substances (NPS). <i>Current Topics in Behavioral Neurosciences</i> , 2017, , .	0.8	17
80	Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. <i>Psychopharmacology</i> , 2017, 234, 2031-2046.	1.5	117
81	Multipotent and Poly-therapeutic Fungal Alkaloids of <i>Claviceps purpurea</i> . <i>Medicinal and Aromatic Plants of the World</i> , 2017, , 229-252.	0.1	1
82	Effect of Psilocybin on Empathy and Moral Decision-Making. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 747-757.	1.0	134
83	Psilocybin for treating substance use disorders?. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 203-212.	1.4	56
84	Novel Psychoactive Substancesâ€™Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs. <i>Frontiers in Psychiatry</i> , 2017, 8, 152.	1.3	40
85	The Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary Psychology. <i>Frontiers in Neuroscience</i> , 2017, 11, 539.	1.4	45
86	Serotonin receptors in depression: from A to B. <i>F1000Research</i> , 2017, 6, 123.	0.8	121
87	Crosstalk Between 5-HT2A and mGlu2 Receptors: Implications in Schizophrenia and Its Treatment. , 2018, , 147-189.		1
88	Horizontal gene cluster transfer increased hallucinogenic mushroom diversity. <i>Evolution Letters</i> , 2018, 2, 88-101.	1.6	73
89	Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders. , 2018, , 199-220.		3
90	Metabolism of the tryptamineâ€derived new psychoactive substances 5â€MeOâ€2â€Meâ€DALT, 5â€MeOâ€2â€Meâ€ALCHT, and 5â€MeOâ€2â€Meâ€DIPT and their detectability in urine studied by GCâ€MS, LCâ€MSⁿ, and LCâ€HRâ€MS/MS. <i>Drug Testing and Analysis</i> , 2018, 10, 184-195.		
91	Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSMâ€775). <i>Drug Testing and Analysis</i> , 2018, 10, 310-322.	1.6	40
92	Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). <i>Neuropharmacology</i> , 2018, 134, 141-148.	2.0	32
93	TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above?. <i>Neuropharmacology</i> , 2018, 142, 20-29.	2.0	17
94	Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. <i>Biochemical Pharmacology</i> , 2018, 158, 27-34.	2.0	47

#	ARTICLE	IF	CITATIONS
95	Reproductive Aging: Perimenopause and Psychopathological Symptoms. , 0, , .		3
96	Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs. <i>Pharmacological Reviews</i> , 2018, 70, 684-711.	7.1	39
97	DARK Classics in Chemical Neuroscience: Psilocybin. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2438-2447.	1.7	68
98	Exposure to ayahuasca induces developmental and behavioral alterations on early life stages of zebrafish. <i>Chemico-Biological Interactions</i> , 2018, 293, 133-140.	1.7	19
99	Dark Classics in Chemical Neuroscience: <i>N,N</i> -Dimethyltryptamine (DMT). <i>ACS Chemical Neuroscience</i> , 2018, 9, 2344-2357.	1.7	70
100	<i>N,N</i> -Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. <i>Frontiers in Neuroscience</i> , 2018, 12, 536.	1.4	90
101	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. <i>Neuropharmacology</i> , 2018, 142, 143-166.	2.0	184
102	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.	2.0	121
103	Ayahuasca: Uses, Phytochemical and Biological Activities. <i>Natural Products and Bioprospecting</i> , 2019, 9, 251-265.	2.0	26
104	Biosynthesis and Extracellular Concentrations of <i>N,N</i> -dimethyltryptamine (DMT) in Mammalian Brain. <i>Scientific Reports</i> , 2019, 9, 9333.	1.6	48
105	Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats. <i>Neurotoxicity Research</i> , 2019, 36, 91-100.	1.3	36
106	Classic psychedelics: the special role of the visual system. <i>Reviews in the Neurosciences</i> , 2019, 30, 651-669.	1.4	6
107	Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines. <i>Frontiers in Pharmacology</i> , 2019, 10, 1423.	1.6	15
108	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. , 2019, 197, 83-102.		296
109	DARK Classics in Chemical Neuroscience: NBOMes. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3860-3869.	1.7	39
110	Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. <i>Neuropharmacology</i> , 2020, 167, 107933.	2.0	132
111	The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 264, 123-129.	2.0	50
112	Toxin-Induced Acute Delirium. <i>Neurologic Clinics</i> , 2020, 38, 781-798.	0.8	5

#	ARTICLE	IF	CITATIONS
113	Hallucinogens' psychedelics and dissociative drugs. , 2020, , 295-303.		1
114	Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use. ACS Omega, 2020, 5, 32067-32075.	1.6	15
115	Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact. Pharmaceuticals, 2020, 13, 334.	1.7	45
116	The therapeutic potential of microdosing psychedelics in depression. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532095056.	1.2	42
117	Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models. Frontiers in Neuroscience, 2020, 14, 43.	1.4	29
118	Synthesis and characterization of high-purity N,N -dimethyltryptamine hemifumarate for human clinical trials. Drug Testing and Analysis, 2020, 12, 1483-1493.	1.6	6
119	Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains. NeuroImage, 2020, 220, 117049.	2.1	49
120	Understanding the neurobiological effects of drug abuse: Lessons from zebrafish models. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109873.	2.5	23
121	Designer drugs: mechanism of action and adverse effects. Archives of Toxicology, 2020, 94, 1085-1133.	1.9	138
122	Serotonin and schizophrenia. Handbook of Behavioral Neuroscience, 2020, 31, 711-743.	0.7	7
123	Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. NeuroImage, 2021, 225, 117456.	2.1	25
124	A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics. Trends in Neurosciences, 2021, 44, 260-275.	4.2	58
125	5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence. Progress in Brain Research, 2021, 259, 229-263.	0.9	3
126	Pharmacology and Neurotoxicity of 5-MeO-DIPT. , 2021, , 1-12.		0
127	Behavioral arrest and a characteristic slow waveform are hallmark responses to selective 5-HT2A receptor activation. Scientific Reports, 2021, 11, 1925.	1.6	9
128	Neural Correlates of the Shamanic State of Consciousness. Frontiers in Human Neuroscience, 2021, 15, 610466.	1.0	15
129	Actual Concepts of Higher Fungi's Toxins: Simple Nitrogen-Containing Compounds. Biology Bulletin Reviews, 2021, 11, 198-212.	0.3	5
130	Psychoactive Substances of Natural Origin: Toxicological Aspects, Therapeutic Properties and Analysis in Biological Samples. Molecules, 2021, 26, 1397.	1.7	14

#	ARTICLE	IF	CITATIONS
131	Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT _{2R} activation in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	173
132	The Therapeutic Potential of Psilocybin. <i>Molecules</i> , 2021, 26, 2948.	1.7	78
133	Catalysts for change: the cellular neurobiology of psychedelics. <i>Molecular Biology of the Cell</i> , 2021, 32, 1135-1144.	0.9	21
134	Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responses—A Simultaneous EEG—fMRI Study. <i>Cerebral Cortex</i> , 2021, 32, 186-196.	1.6	15
135	Psychonauts™ psychedelics: A systematic, multilingual, web-crawling exercise. <i>European Neuropsychopharmacology</i> , 2021, 49, 69-92.	0.3	13
136	Pharmacologic Similarities and Differences Among Hallucinogens. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S100-S113.	1.0	4
137	Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6/SvEv mice. <i>Psychopharmacology</i> , 2022, 239, 1649-1664.	1.5	12
138	Rediscovering Psilocybin as an Antidepressive Treatment Strategy. <i>Pharmaceuticals</i> , 2021, 14, 985.	1.7	8
139	The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 739053.	1.6	11
140	Neuropsychological Functioning in Users of Serotonergic Psychedelics — A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 739966.	1.6	4
141	Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. <i>Psychopharmacology</i> , 2021, 238, 341-354.	1.5	70
142	Substance Use Disorders: Cognitive Sequelae, Behavioral Manifestations, Neuroimaging Correlates, and Novel Interventions. , 2019, , 697-728.		2
143	Halluzinogene. , 2019, , 223-235.		1
144	Re-evaluation of the discriminative stimulus effects of lysergic acid diethylamide with male and female Sprague-Dawley rats. <i>Behavioural Pharmacology</i> , 2020, 31, 776-786.	0.8	4
145	Phase I Hydroxylated Metabolites of the K ₂ Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity. <i>PLoS ONE</i> , 2011, 6, e21917.	1.1	192
146	The pharmacological interaction of compounds in ayahuasca: a systematic review. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 646-656.	0.9	18
147	Four Novel Synthetic Tryptamine Analogs Induce Head-Twitch Responses and Increase 5-HT _{2a} in the Prefrontal Cortex in Mice. <i>Biomolecules and Therapeutics</i> , 2020, 28, 83-91.	1.1	9
148	Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies. <i>Neural Regeneration Research</i> , 2020, 15, 802.	1.6	30

#	ARTICLE	IF	CITATIONS
149	Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States. <i>Frontiers in Psychiatry</i> , 2021, 12, 706017.	1.3	22
150	Epidemiological dynamics of addiction.. , 2012, , 67-102.		1
151	Lysergic Acid Diethylamide and Mescaline. , 0, , 135-152.		0
152	Psychedelika. , 2017, , 1-19.		0
154	12 The Diagnosis and Management of Substance Use Disorders in the Emergency. , 2017, , 199-234.		0
155	Psychedelika. , 2018, , 669-682.		0
156	Freizeitgebrauch von LSD und Psilocybin-Pilzen. , 2019, , 511-529.		0
159	A potential role for psilocybin in the treatment of obsessive-compulsive disorder. <i>Journal of Psychedelic Studies</i> , 2020, 4, 77-87.	0.5	2
160	A narrative synthesis of research with 5-MeO-DMT. <i>Journal of Psychopharmacology</i> , 2022, 36, 273-294.	2.0	28
161	Molecular Mechanisms of Action of Stimulant Novel Psychoactive Substances (NPS) that target the High-affinity Transporter for Dopamine. <i>Neuronal Signaling</i> , 2021, 5, NS20210006.	1.7	3
162	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. <i>Psychopharmacology</i> , 2022, 239, 1425-1440.	1.5	13
164	Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors. <i>Pharmaceuticals</i> , 2021, 14, 1213.	1.7	15
165	Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. <i>CNS Drugs</i> , 2022, 36, 17-30.	2.7	45
166	Microdosing psychedelics as cognitive and emotional enhancers.. <i>Psychology of Consciousness: Theory Research, and Practice</i> , 2020, 7, 316-329.	0.3	2
167	Acute sleep deprivation upregulates serotonin 2A receptors in the frontal cortex of mice via the immediate early gene Egr3. <i>Molecular Psychiatry</i> , 2022, 27, 1599-1610.	4.1	8
169	Photoswitchable Serotonins for Optical Control of the 5-HT _{2A} Receptor**. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	2
170	The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. <i>Journal of Psychopharmacology</i> , 2022, 36, 114-125.	2.0	47
171	Photoswitchable Serotonins for Optical Control of the 5-HT _{2A} Receptor**. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	25

#	ARTICLE	IF	CITATIONS
172	The clinical pharmacology and potential therapeutic applications of 5- <i>N,N</i> -dimethyltryptamine (5-MeO-DMT). <i>Journal of Neurochemistry</i> , 2022, 162, 128-146.	2.1	31
173	Effects of the 5-HT _{2A} receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. <i>Psychopharmacology</i> , 2022, 239, 1665-1677.	1.5	16
174	Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 290.	1.5	8
175	Automated Computer Software Assessment of 5-Hydroxytryptamine 2A Receptor-Mediated Head Twitch Responses from Video Recordings of Mice. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 321-330.	2.5	9
176	Development of an <i>E. coli</i> -based norbaeocystin production platform and evaluation of behavioral effects in rats. <i>Metabolic Engineering Communications</i> , 2022, 14, e00196.	1.9	8
177	Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. <i>Molecules</i> , 2022, 27, 2520.	1.7	14
178	Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 761-776.	1.0	13
181	Therapeutic Properties of Ayahuasca Components in Ischemia/Reperfusion Injury of the Eye. <i>Biomedicines</i> , 2022, 10, 997.	1.4	1
182	Do psychedelics change beliefs?. <i>Psychopharmacology</i> , 2022, 239, 1809-1821.	1.5	7
183	Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 138, 104689.	2.9	45
184	Unraveling the Mysteries of Mental Illness With Psilocybin. <i>Cureus</i> , 2022, , .	0.2	1
186	Psilocybin for Trauma-Related Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 319-332.	0.8	7
187	Neural mechanisms underlying psilocybin's therapeutic potential – the need for preclinical in vivo electrophysiology. <i>Journal of Psychopharmacology</i> , 2022, 36, 781-793.	2.0	13
188	Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice. <i>Journal of Psychopharmacology</i> , 2022, 36, 860-874.	2.0	11
189	Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6713.	1.8	29
190	Acute behavioral and Neurochemical Effects of Novel <i>N</i> -Benzyl-2-Phenylethylamine Derivatives in Adult Zebrafish. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1902-1922.	1.7	4
191	Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
192	Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 140, 104793.	2.9	54

#	ARTICLE	IF	CITATIONS
193	Serotonin 5-HT _{2A} , 5-HT _{2c} and 5-HT _{1A} receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twitch response. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113612.	2.5	22
194	Overview of analytical methods for determining novel psychoactive substances, drugs and their metabolites in biological samples. <i>Critical Reviews in Toxicology</i> , 2022, 52, 239-258.	1.9	2
195	The use of classic psychedelics among adults: a Danish online survey study. <i>Nordic Journal of Psychiatry</i> , 2023, 77, 367-378.	0.7	5
196	Discovery of Î ² -Arrestin-Biased 25CN-NBOH-Derived 5-HT _{2A} Receptor Agonists. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12031-12043.	2.9	11
197	Animal Behavior in Psychedelic Research. <i>Pharmacological Reviews</i> , 2022, 74, 1176-1205.	7.1	5
198	Hallucinogenic Drugs. , 2022, , 267-298.		0
199	Synthetic Cannabinoid Receptor Agonists. , 2022, , 299-328.		0
200	PrÃhistorische Reflexion 2: Anthropologie der HÃhle. , 2022, , 347-428.		0
201	Methods of Lysergic Acid Synthesisâ”The Key Ergot Alkaloid. <i>Molecules</i> , 2022, 27, 7322.	1.7	7
203	Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. <i>Molecular Psychiatry</i> , 2023, 28, 44-58.	4.1	23
205	Structureâ”Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 1181-1196.	2.5	33
206	Signaling underlying kappa opioid receptor-mediated behaviors in rodents. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	3
207	Self-transcendent experiences as promoters of ecological wellbeing? Exploration of the evidence and hypotheses to be tested. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	2
209	Effect of psilocybin on decision-making and motivation in the healthy rat. <i>Behavioural Brain Research</i> , 2023, 440, 114262.	1.2	0
210	Therapeutic use of psilocybin: Practical considerations for dosing and administration. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	13
211	Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. <i>Psychopharmacology</i> , 2023, 240, 27-40.	1.5	5
212	Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. <i>Journal of Psychopharmacology</i> , 2023, 37, 93-106.	2.0	4
213	The association between naturalistic use of psychedelics and co-occurring substance use disorders. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1

#	ARTICLE	IF	CITATIONS
214	Effects of Ketanserin, M100907 and Olanzapine on hallucinogenic like action induced by 2,5-dimethoxy-4-methylamphetamine. <i>Behavioural Pharmacology</i> , 2023, 34, 92-100.	0.8	1
215	The costs and benefits of psychedelics on cognition and mood. <i>Neuron</i> , 2023, 111, 614-630.	3.8	7
216	Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. <i>Neuropharmacology</i> , 2023, 231, 109504.	2.0	7
218	Pharmacology and Neurotoxicity of 5-MeO-DIPT. , 2022, , 1403-1414.		0
219	Rearing behaviour in the mouse behavioural pattern monitor distinguishes the effects of psychedelics from those of lisuride and TBC. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	7
220	Off-target activity of NBOMes and NBOME analogs at the μ opioid receptor. <i>Archives of Toxicology</i> , 2023, 97, 1367-1384.	1.9	1
221	Inhibition of Microglial GSK3 β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles. <i>Biomedicines</i> , 2023, 11, 806.	1.4	7
222	Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy- <i>N,N</i> -dimethyltryptamine in Mice. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 567-577.	2.5	8
223	Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism. <i>Cells</i> , 2023, 12, 963.	1.8	6
224	Natural vs. Synthetic Psilocybin: The Same or Completely Different?. , 2023, , 479-492.		0
237	Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. <i>Molecular Psychiatry</i> , 2023, 28, 3595-3612.	4.1	4
247	Cardiovascular safety of psychedelic medicine: current status and future directions. <i>Pharmacological Reports</i> , 0, , .	1.5	1
250	The possible place for psychedelics in pharmacotherapy of mental disorders. <i>Pharmacological Reports</i> , 2023, 75, 1313-1325.	1.5	2
269	High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin. <i>Molecular Psychiatry</i> , 0, , .	4.1	2